Skip to main content
UniHealth

Doctor search

Rishi Raj, MD

Critical Care (Intensivists) · Stanford

NPI 1730296575

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
1
1 carrier
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

1 plan · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Raj’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence C148274 · Current

Licensed to practise in California · since 2017 · expires 2027-03-31 · Tamil Nadu Dr. M.G.R. Medical University, Christian Medical College, Vellore.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

  • Illinois 036131528Licensed Physician And Surgeon · since 2012 · expires 2017-07-31
    Not RenewedNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend it
    Overall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Good Samaritan Hospital
Clostridium Difficile (C.Diff)Infections0.337BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.75 (0 to 1.67) · 1,340 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.84 (0.54 to 1.14)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths143.59 (98.7 to 188.49) · 98 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 45 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 100 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.7 · 270 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11.3 · 573 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.6 · 820 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.5 · 482 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.3 · 3,711 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.12 (0 to 0.3) · 8,866 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.01 to 0.38) · 9,051 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.65 (0.74 to 4.56) · 1,929 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.8 (0.21 to 3.39) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.33 (0.88 to 3.78) · 1,836 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.73 (0 to 13.46) · 669 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.58 (3.96 to 11.19) · 654 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.59 (0.13 to 3.04) · 496 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.27 (0 to 0.87) · 7,373 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.1 · 152 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections1.08No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.542No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.484No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.565No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.8 · 327 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits24.2 · 703 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits61.1 · 289 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits36.3 · 665 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits25.4 · 856 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits19 · 978 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits6.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits12.3 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits21.2 · 135 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.8 (10.1 to 18.6) · 129 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (0.9 to 1.5) · 531 casesNo differentJan 2024 – Dec 2024

What patients said (704 patients answered, 24% of those asked)

Patient survey stars by topic at Good Samaritan Hospital
Cleanliness3
Nurse communication3
Doctor communication2
Communication about medicines2
Discharge information3
Overall hospital rating2
Quietness1
Recommend hospital3
Share of patients giving the best answer at Good Samaritan Hospital
Room was "always" clean66%
Nurses "always" communicated well75%
Doctors "always" communicated well71%
Staff "always" explained54%
Yes, staff "did" give patients this information83%
Yes, staff "did" give patients information about help after discharge81%
Doctors "always" explained things so they could understand66%
Doctors "always" listened carefully69%
Doctors "always" treated them with courtesy and respect78%
Patients who gave a rating of "9" or "10" (high)63%
Staff "always" explained new medications68%
Nurses "always" explained things so they could understand69%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night38%
"YES", patients would definitely recommend the hospital67%
Staff "always" explained possible side effects40%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$44,891

Medicare paid this office $44,891 for 141 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Critical care, first 30-74 minutes78$35,296$185
Long return visit (40+ min)42$5,296$113

Who their Medicare patients are

141 Original Medicare patients in 2024. Average age 72 · Women 55% · Also on Medicaid 34% · Health risk score 2.44. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.

Conditions among them: High blood pressure 75% · Heart failure 33% · Chronic kidney disease 33% · Coronary heart disease 32% · Atrial fibrillation 31% · Stroke 31% · COPD 30% · Diabetes 28% · Cancer 24% · Depression 18% · Dementia 16%.

The office billed $382,779, Medicare allowed $57,331 and paid $44,891; for 282 services of 14 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024141282722.44$382,779$44,891
2023214542732.85$757,199$90,541
2022191403742.25$457,223$65,221
2021231564741.69$274,345$60,200
2020177414742.19$252,718$44,278
2019286534742.15$110,572$39,584
20185401,210722.15$180,856$56,217
2017438863712.22$234,521$59,313
20164711,208702.34$372,126$88,545
20154481,207712.35$407,565$98,309
20143591,015712.36$366,692$89,516
2013321809692.62$295,834$71,627

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Critical care, first 30-74 minutes117$72,678$192
Long return visit (40+ min)73$10,759$118
New patient visit (60+ min)18$2,539$141
Critical care, each additional 30 minutes12$2,316$96

2022: 3 services

Original Medicare services billed in 2022
Critical care, first 30-74 minutes64$42,149$196
Long return visit (40+ min)98$14,777$117
New patient visit (60+ min)27$4,675$173

2021: 7 services

Original Medicare services billed in 2021
Long return visit (40+ min)111$26,697$149
Critical care, first 30-74 minutes42$23,165$198
New patient visit (60+ min)31$6,361$205
Test to examine how well the lungs exchange gases94$784$8
Test to measure expiratory airflow and volume85$655$8
Test to measure expiratory airflow and volume changes before and after medication administration18$174$10
Test to determine lung volumes using sensors14$158$11

2020: 6 services

Original Medicare services billed in 2020
Critical care, first 30-74 minutes34$20,970$204
Long return visit (40+ min)97$14,225$99
New patient visit (60+ min)20$3,060$153
Return visit (30+ min)24$1,358$52
Test to examine how well the lungs exchange gases37$317$9
Test to measure expiratory airflow and volume35$278$8

2019: 13 services

Original Medicare services billed in 2019
Long return visit (40+ min)79$10,797$98
Return visit (30+ min)75$5,973$71
New patient visit (60+ min)41$5,640$138
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$3,490$94
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes20$2,178$66
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,733$124
New patient visit (45+ min)15$1,727$115
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes14$1,272$91
Short return visit (20+ min)16$836$46
Test to examine how well the lungs exchange gases42$350$8
Test to measure expiratory airflow and volume42$324$8
Test to measure expiratory airflow and volume changes before and after medication administration24$276$12
Test to determine lung volumes using sensors14$150$11

2018: 16 services

Original Medicare services billed in 2018
Long return visit (40+ min)103$14,558$97
New patient visit (60+ min)63$9,343$148
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes41$5,622$65
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes31$3,789$122
Return visit (30+ min)42$3,498$70
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$3,370$94
New patient visit (60+ min)17$2,757$162
Test to examine how well the lungs exchange gases244$2,046$8
Irrigation and suction of lung airways to obtain cells using an endoscope14$1,722$123
Test to measure expiratory airflow and volume changes before and after medication administration139$1,636$12
New patient visit (45+ min)15$1,499$100
Test to measure expiratory airflow and volume146$1,126$7
Test to determine lung volumes using sensors93$1,033$11
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes11$988$90
Test to measure expiratory airflow and volume36$297$7
Test to determine lung volumes using gas dilution or washout19$200$11

2017: 18 services

Original Medicare services billed in 2017
Critical care, first 30-74 minutes22$9,623$178
Return visit (30+ min)100$9,061$78
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes53$8,024$86
New patient visit (60+ min)40$6,013$150
Long return visit (40+ min)38$4,882$100
Long return visit (40+ min)23$3,407$114
New patient visit (60+ min)20$3,403$170
New patient visit (45+ min)26$3,117$120
Initial hospital care with moderate level of medical decision making at least 75 minutes11$1,994$181
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,687$120
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,298$62
Test to examine how well the lungs exchange gases107$859$8
Pulmonary exercise testing13$690$46
Test to measure expiratory airflow and volume changes before and after medication administration53$621$12
Test to determine lung volumes using sensors56$601$11
Test to measure expiratory airflow and volume65$477$7
Test to measure expiratory airflow and volume33$473$14
Test to determine lung volumes using gas dilution or washout13$135$10

2016: 18 services

Original Medicare services billed in 2016
Critical care, first 30-74 minutes42$18,516$191
Return visit (30+ min)125$14,825$86
Long return visit (40+ min)69$14,291$114
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes79$10,908$88
New patient visit (45+ min)59$7,973$135
New patient visit (60+ min)31$5,291$171
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,407$172
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes29$2,369$61
Pulmonary exercise testing37$1,927$47
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes16$1,732$108
Test to examine how well the lungs exchange gases127$980$8
Test to determine lung volumes using sensors78$802$10
Test to examine how well the lungs exchange gases14$724$45
Test to measure expiratory airflow and volume19$676$29
Test to measure expiratory airflow and volume90$644$7
Test to determine lung volumes using gas dilution or washout14$560$35
Test to determine lung volumes using gas dilution or washout47$485$10
Test to measure expiratory airflow and volume changes before and after medication administration40$428$11

2015: 18 services

Original Medicare services billed in 2015
Critical care, first 30-74 minutes70$32,771$193
Long return visit (40+ min)71$15,083$120
Return visit (30+ min)85$11,451$85
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes86$11,309$88
New patient visit (45+ min)42$5,550$132
New patient visit (60+ min)23$3,773$164
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,109$173
Pulmonary exercise testing47$2,650$46
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes32$2,612$61
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes22$2,560$116
Test to measure expiratory airflow and volume27$996$30
Test to examine how well the lungs exchange gases112$824$7
Test to examine how well the lungs exchange gases15$725$45
Test to determine lung volumes using sensors70$686$10
Test to determine lung volumes using gas dilution or washout15$561$35
Test to measure expiratory airflow and volume74$505$7
Test to measure expiratory airflow and volume changes before and after medication administration40$404$10
Test to determine lung volumes using gas dilution or washout40$393$10

2014: 15 services

Original Medicare services billed in 2014
Critical care, first 30-74 minutes61$36,955$190
Return visit (30+ min)81$10,588$83
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes64$10,120$87
Long return visit (40+ min)36$7,352$113
New patient visit (45+ min)27$3,662$136
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes38$3,276$61
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes27$3,182$118
Initial hospital care with moderate level of medical decision making at least 75 minutes16$2,764$173
Pulmonary exercise testing38$2,664$46
Test to examine how well the lungs exchange gases77$590$8
Test to determine lung volumes using sensors41$416$10
Test to measure expiratory airflow and volume changes before and after medication administration36$395$11
Administration of influenza virus vaccine12$311$26
Test to measure expiratory airflow and volume43$303$7
Test to determine lung volumes using gas dilution or washout11$114$10

2013: 15 services

Original Medicare services billed in 2013
Critical care, first 30-74 minutes84$34,809$181
Return visit (30+ min)39$5,391$87
Long return visit (40+ min)23$4,459$121
New patient visit (45+ min)32$4,385$137
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes40$4,207$86
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes26$2,966$114
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes26$2,125$56
Pulmonary exercise testing24$1,580$48
Test to examine how well the lungs exchange gases16$885$52
Test to determine lung volumes using gas dilution or washout15$634$40
Test to examine how well the lungs exchange gases77$618$8
Test to measure expiratory airflow and volume changes before and after medication administration33$356$11
Test to measure expiratory airflow and volume46$318$7
Test to determine lung volumes using sensors15$162$11
Test to determine lung volumes using gas dilution or washout11$119$11

Medicaid work

$11,738 in 2024

Medicaid paid $11,738 for 115 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes115$11,738
Medicaid work by year
2024115115$11,738
2023267120$30,904
2022121123$13,349
202126214$90
202093119$9,027
201960418$690
2018149423$1,245
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes267$30,904

2022

Largest Medicaid services in 2022
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes121$13,349

2021

Largest Medicaid services in 2021
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation12$48
Diffusing capacity14$42

2020

Largest Medicaid services in 2020
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes93$9,027

2019

Largest Medicaid services in 2019
EVALUATION OF WHEEZING19$303
Plethysmography for determination of lung volumes and, when performed, airway resistance12$158
Diffusing capacity17$137
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation12$92

2018

Largest Medicaid services in 2018
EVALUATION OF WHEEZING46$568
Diffusing capacity65$403
Plethysmography for determination of lung volumes and, when performed, airway resistance26$193
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation12$80

Drugs they prescribed that Part D paid

$1,423,312

Pharmacies billed $1,423,312 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 219) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.

84 generic and 135 brand-name prescriptions · $1,423,312 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Ofev123$1,385,357$11,263
Pirfenidone37$24,902$673
Methotrexate13$714$55

Year by year

Part D prescribing by year
2024219320% (0)62%$1,423,312
2023298390% (0)59%$1,788,059
2022365490% (0)68%$2,769,684
2021296530% (0)70%$1,943,298
2020389500% (0)49%$1,672,931
2019328540% (0)38%$1,125,043
201829967None36%$752,996
201741375None43%$692,615
201658471None44%$901,334
201547461None39%$800,940
201431243None19%$43,152
2013161470% (0)42%$193,376

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 6 drugs

Part D drugs prescribed in 2023
Ofev141$1,658,810$11,765
Pirfenidone45$98,768$2,195
Trelegy Ellipta17$10,787$635
Mycophenolate Mofetil11$5,576$507
Methotrexate19$1,166$61
Prednisone18$185$10

2022: 6 drugs

Part D drugs prescribed in 2022
Ofev210$2,393,006$11,395
Pirfenidone36$185,702$5,158
Esbriet19$163,965$8,630
Mycophenolate Mofetil16$6,804$425
Methotrexate17$791$47
Prednisone22$311$14

2021: 6 drugs

Part D drugs prescribed in 2021
Ofev149$1,675,895$11,248
Esbriet22$237,543$10,797
Mycophenolate Mofetil12$4,189$349
Methotrexate20$822$41
Prednisone30$391$13
Sulfamethoxazole-Trimethoprim15$118$8

2020: 7 drugs

Part D drugs prescribed in 2020
Ofev133$1,414,233$10,633
Esbriet23$225,975$9,825
Mycophenolate Mofetil61$9,064$149
Spiriva13$8,799$677
Methotrexate25$930$37
Prednisone39$367$9
Sulfamethoxazole-Trimethoprim35$110$3

2019: 7 drugs

Part D drugs prescribed in 2019
Ofev106$1,060,386$10,004
Mycophenolic Acid14$6,867$490
Mycophenolate Mofetil58$6,202$107
Azathioprine32$1,055$33
Methotrexate12$831$69
Prednisone33$513$16
Sulfamethoxazole-Trimethoprim35$191$5

2018: 6 drugs

Part D drugs prescribed in 2018
Ofev77$729,166$9,470
Advair Diskus12$4,719$393
Mycophenolate Mofetil34$2,787$82
Prednisone44$520$12
Omeprazole14$279$20
Sulfamethoxazole-Trimethoprim61$242$4

2017: 13 drugs

Part D drugs prescribed in 2017
Esbriet56$472,542$8,438
Ofev19$166,508$8,764
Spiriva17$9,831$578
Breo Ellipta20$9,484$474
Advair Diskus18$7,547$419
Symbicort14$4,375$312
Azathioprine15$1,228$82
Mycophenolate Mofetil16$1,197$75
Fluticasone Propionate35$451$13
Prednisone32$377$12
Omeprazole19$309$16
Sulfamethoxazole-Trimethoprim65$271$4
Montelukast16$139$9

2016: 14 drugs

Part D drugs prescribed in 2016
Esbriet80$650,335$8,129
Ofev22$186,794$8,491
Spiriva36$14,597$405
Symbicort42$14,081$335
Advair Diskus15$6,623$442
Mycophenolate Mofetil13$1,258$97
Azathioprine33$1,151$35
Proair Hfa12$659$55
Prednisone45$596$13
Fluticasone Propionate53$546$10
Sulfamethoxazole-Trimethoprim64$357$6
Omeprazole20$350$17
Azithromycin15$249$17
Alendronate13$112$9

2015: 17 drugs

Part D drugs prescribed in 2015
Esbriet65$510,927$7,860
Ofev30$243,620$8,121
Atovaquone13$13,182$1,014
Symbicort25$7,130$285
Mycophenolate Mofetil23$2,554$111
Qvar12$2,245$187
Tacrolimus11$1,627$148
Proair Hfa15$779$52
Azathioprine18$705$39
Omeprazole35$425$12
Prednisone30$422$14
Fluticasone Propionate27$243$9
Sulfamethoxazole-Trimethoprim39$236$6
Montelukast13$184$14
Amlodipine Besylate12$66$5
Pantoprazole12$64$5
Metoprolol11$45$4

2014: 12 drugs

Part D drugs prescribed in 2014
Tacrolimus15$2,569$171
Mycophenolate Mofetil19$1,609$85
Qvar11$1,499$136
Azathioprine17$505$30
Prednisone33$330$10
Fluticasone Propionate14$284$20
Alendronate24$208$9
Omeprazole13$160$12
Sulfamethoxazole-Trimethoprim24$132$5
Azithromycin13$132$10
Pantoprazole12$70$6
Metoprolol12$49$4

2013: 2 drugs

Part D drugs prescribed in 2013
Tracleer24$162,670$6,778
Fluticasone Propionate11$234$21

Money from drug and device companies

$402 in 2025

Industry payments by year
202513None$402
202312$2,883$2,883
202227$1,575$1,727
202111None$14
202012$3,900$3,905

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Boehringer Ingelheim PharmaceuticalsOfev$402
3 payments
  • Meals · 2025-06-05 · $125
  • Meals for Ofev · 2025-05-20 · $131
  • Meals · 2025-05-18 · $147
See all 3 published payments
Every published payment
Boehringer Ingelheim PharmaceuticalsMeals · 2025-06-05None$125
Boehringer Ingelheim PharmaceuticalsMeals · 2025-05-20Ofev$131
Boehringer Ingelheim PharmaceuticalsMeals · 2025-05-18None$147
See earlier years (2023, 2022, 2021, 2020)

2023: $2,883

Payments by company in 2023
Boehringer Ingelheim PharmaceuticalsOfev$2,883
2 payments
  • Paid to speak or teach for Ofev · 2023-04-05 · $661
  • Paid to speak or teach for Ofev · 2023-01-08 · $2,223

2022: $1,727

Payments by company in 2022
Boehringer Ingelheim PharmaceuticalsOfev$1,575
6 payments
  • Paid to speak or teach for Ofev · 2022-10-02 · $327
  • Paid to speak or teach for Ofev · 2022-10-02 · $327
  • Paid to speak or teach for Ofev · 2022-08-04 · $58
  • Paid to speak or teach for Ofev · 2022-08-04 · $58
  • Paid to speak or teach for Ofev · 2022-05-16 · $556
  • Paid to speak or teach for Ofev · 2022-01-13 · $248
Intuitive SurgicalDa Vinci Surgical System$153
1 payment
  • Meals for Da Vinci Surgical System · 2022-11-15 · $153

2021: $14

Payments by company in 2021
Melinta TherapeuticsKimyrsa$14
1 payment
  • Meals for Kimyrsa · 2021-08-16 · $14

2020: $3,905

Payments by company in 2020
Boehringer Ingelheim PharmaceuticalsOfev$3,905
2 payments
  • Consulting for Ofev · 2020-12-29 · $3,900
  • Education · 2020-07-31 · $5

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Boehringer Ingelheim Pharmaceuticals, Inc. · Outcome-Based Quantitative Radiologic Biomarkers for Ild · 2024Their institution$200,000
United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2024Their institution$134,240
E.R. Squibb & Sons, L.L.C. · A Study To Evaluate the Efficacy, Safety, and Tolerability of Bms-986278 in Participants With Idiopathic Pulmonary Fibrosis · 2025Their institution$128,766
United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2023Their institution$121,419
United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2024Their institution$108,108
E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2022Their institution$106,680
Roche Products Limited · Trial To Evaluate the Efficacy and Safety of Prm 151 in Patients With Idiopathic Pulmonary Fibrosis · 2022Their institution$100,735
Boehringer Ingelheim Pharmaceuticals, Inc. · Towards Outcomes-Based Quantitative Radiologic Biomarkers for Interstitial Lung Diseases · 2025Their institution$100,000
Boehringer Ingelheim Pharmaceuticals, Inc. · Outcome Based Quantitative Radiologic Biomarkers F · 2023Their institution$100,000
E.R. Squibb & Sons, L.L.C. · A Study To Evaluate the Efficacy, Safety, and Tolerability of Bms-986278 in Participants With Progressive Pulmonary Fibrosis · 2025Their institution$96,747
United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2025Their institution$81,493
United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2025Their institution$68,650
Roche Products Limited · Ph III Ole Trial To Evaluate Long Term Safety and Efficacy of Prm 151 in Patients With Ipf · 2023Their institution$59,230
E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2023Their institution$50,733
United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (Teton-Ppf) · 2025Their institution$45,938
Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2021Their institution$40,448
E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2021Their institution$39,290
Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2023Their institution$38,786
United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (Teton-Ppf) · 2024Their institution$35,742
Roche Products Limited · Trial To Evaluate the Efficacy and Safety of Prm 151 in Patients With Idiopathic Pulmonary Fibrosis · 2023Their institution$30,960
Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2024Their institution$30,899
Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2020Their institution$30,331
Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2019Their institution$22,918
United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2022Their institution$22,492
Boehringer Ingelheim Pharmaceuticals, Inc. · Pulmonary Rehabilitation and Nintedanib in Ipf · 2019Their institution$14,216
Celgene Corporation · Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (Jk-Ipf-Pi-0004) · 2019Their institution$13,056
Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2022Their institution$10,892
Boehringer Ingelheim Pharmaceuticals, Inc. · Idiopathic Pulmonary Fibrosis Prospective Outcome Registry · 2025Their institution$6,130
E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2024Their institution$5,531
Boehringer Ingelheim Pharmaceuticals, Inc. · Pulmonary Rehabilitation and Nintedanib in Ipf · 2020Their institution$4,557
Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2019This clinician$3,335
E.R. Squibb & Sons, L.L.C. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of Bms-986278 in Participants With Pulmonary Fibrosis · 2025Their institution$3,010

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1730296575
Licence
CA C148274, IL 036.131528California C148274: Current · expires 2027-03-31Illinois 036131528: Not Renewed
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RS0012X (207RS0012X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-08-25
NPI last updated
2025-02-10
NPI record certified
2025-02-10

This is when the NPI record was last certified, not a medical board exam.